PROM1 and glioblastoma: Together, the present results demonstrate that CD133+ U251R cells were more resistant to TMZ treatment than CD133− U251R cells although no significant differences were observed in MGMT protein expression levels between them, the major mediator of TMZ resistance in GBM.